Neurocrine Biosciences, Inc. Stock price

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:50 2024-03-04 pm EST 5-day change 1st Jan Change
133.1 USD +1.38% Intraday chart for Neurocrine Biosciences, Inc. -1.82% +1.02%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 2.21B Sales 2025 * 2.52B Capitalization 13.07B
Net income 2024 * 490M Net income 2025 * 653M EV / Sales 2024 * 4.87 x
Net cash position 2024 * 2.28B Net cash position 2025 * 3.03B EV / Sales 2025 * 3.98 x
P/E ratio 2024 *
28 x
P/E ratio 2025 *
20.9 x
Employees 1,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.54%
More Fundamentals * Assessed data
Dynamic Chart
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing MT
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment CI
Neurocrine Biosciences Insider Sold Shares Worth $1,987,047, According to a Recent SEC Filing MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating MT
Neurocrine Biosciences Insider Sold Shares Worth $376,700, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $313,530, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $290,968, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $359,041, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $737,271, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $270,284, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $352,612, According to a Recent SEC Filing MT
Deutsche Bank Raises Neurocrine Biosciences Price Target to $161 From $160, Maintains Buy Rating MT
Citigroup Trims Price Target on Neurocrine Biosciences to $140 From $141, Maintains Neutral Rating MT
Mizuho Securities Raises Price Target on Neurocrine Biosciences to $140 From $116, Maintains Neutral Rating MT
More news
1 day+1.38%
1 week-1.82%
Current month+2.08%
1 month-6.09%
3 months+14.23%
6 months+20.32%
Current year+1.02%
More quotes
1 week
129.15
Extreme 129.15
136.10
1 month
128.00
Extreme 128
143.16
Current year
128.00
Extreme 128
143.35
1 year
89.04
Extreme 89.04
143.35
3 years
71.88
Extreme 71.875
143.35
5 years
71.85
Extreme 71.85
143.35
10 years
12.17
Extreme 12.17
143.35
More quotes
Managers TitleAgeSince
Founder 66 91-12-31
Director of Finance/CFO 44 17-10-31
Chief Tech/Sci/R&D Officer 60 21-11-29
Members of the board TitleAgeSince
Director/Board Member 75 99-03-31
Director/Board Member 72 15-09-30
Founder 66 91-12-31
More insiders
Date Price Change Volume
24-03-04 133.1 +1.39% 962,863
24-03-01 131.3 +0.69% 1,322,141
24-02-29 130.4 -3.16% 1,717,387
24-02-28 134.7 -1.01% 842,212
24-02-27 136 +0.33% 818,609

Delayed Quote Nasdaq, March 04, 2024 at 03:59 pm EST

More quotes
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson's disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
133.1 USD
Average target price
149.7 USD
Spread / Average Target
+12.44%
Consensus
  1. Stock
  2. Equities
  3. Stock Neurocrine Biosciences, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW